About: Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Psoriasis vulgaris is recently associated with other comorbidities like metabolic syndrome and cardiovascular disease. Some studies have also shown connection to celiac disease, a multisystemic disorder associated with skin manifestations like dermatitis herpetiformis Duhring as well as the systemic symptoms. Coexistence of psoriasis vulgaris and celiac disease has been supported by strong evidence. Cianci et al. have shown an increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis which suggests a related genetic predisposition in the pathogenesis of these diseases. On the other hand, association with dermatitis herpetiformis is very rare with only some anecdotal reports. Most of these patients were treated only by gluten-free diet or in combination with dapsone. To the best of our knowledge, none of these patients had been on a biologic agent and therefore there is no clinical evidence so far on the safety of combinations of sulfones and biologics. Our patient used ustekinumab in combination with dapsone for over a year with no adverse event. At present, his psoriasis and dermatitis herpetiformis remain under control. It is under discussion whether ustekinumab could trigger dermatitis herpetiformis. We tend not to support this hypothesis because the activity of neutrophils should not be influenced by this drug. The number of patients treated with biologics is rapidly increasing and new challenging cases will arise as biologic drugs are combined with other immunomodulatory agents.
  • Psoriasis vulgaris is recently associated with other comorbidities like metabolic syndrome and cardiovascular disease. Some studies have also shown connection to celiac disease, a multisystemic disorder associated with skin manifestations like dermatitis herpetiformis Duhring as well as the systemic symptoms. Coexistence of psoriasis vulgaris and celiac disease has been supported by strong evidence. Cianci et al. have shown an increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis which suggests a related genetic predisposition in the pathogenesis of these diseases. On the other hand, association with dermatitis herpetiformis is very rare with only some anecdotal reports. Most of these patients were treated only by gluten-free diet or in combination with dapsone. To the best of our knowledge, none of these patients had been on a biologic agent and therefore there is no clinical evidence so far on the safety of combinations of sulfones and biologics. Our patient used ustekinumab in combination with dapsone for over a year with no adverse event. At present, his psoriasis and dermatitis herpetiformis remain under control. It is under discussion whether ustekinumab could trigger dermatitis herpetiformis. We tend not to support this hypothesis because the activity of neutrophils should not be influenced by this drug. The number of patients treated with biologics is rapidly increasing and new challenging cases will arise as biologic drugs are combined with other immunomodulatory agents. (en)
Title
  • Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring
  • Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring (en)
skos:prefLabel
  • Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring
  • Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring (en)
skos:notation
  • RIV/00064173:_____/12:43906095!RIV13-MZ0-00064173
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • S, V
http://linked.open...iv/cisloPeriodika
  • 12
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 147427
http://linked.open...ai/riv/idVysledku
  • RIV/00064173:_____/12:43906095
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Duhring; herpetiformis; dermatitis; psoriasis; dapsone; ustekinumab; Long-term combination therapy (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [24C53751C714]
http://linked.open...i/riv/nazevZdroje
  • Journal of Dermatology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 39
http://linked.open...iv/tvurceVysledku
  • Arenberger, Petr
  • Arenbergerová, Monika
  • Gkalpakiotis, Spyridon
  • Sticová, Eva
  • Šefrnová, Petra
http://linked.open...ain/vavai/riv/wos
  • 000311615300001
issn
  • 0385-2407
number of pages
http://bibframe.org/vocab/doi
  • 10.1111/j.1346-8138.2012.01630.x
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software